AnaptysBio’s drug candidates rosnilimab and ANB032 hold key trial results ahead. Find out why ANAB stock is impacted by ...

Jefferies London Healthcare Conference November 20, 2024 10:00 AM ETCompany ParticipantsWetteny Joseph - CFOConference ...

Concerto Biosciences has dosed the first subject in a Phase I trial of the three-stain live biotherapeutic product, ENS-002, ...

Aclaris Therapeutics has secured an exclusive license from Biosion for the global rights to two new antibodies.

Enhances Aclaris’ pipeline with complementary biologics portfolio -- Expands leadership team with addition of seasoned ...